Bal Pharma Limited (BALPHARMA.BO)
INR 111.73
(1.87%)
INR 111.73
(1.87%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 363.82 Million INR | 14.6% |
| 2022 | 317.48 Million INR | 8.48% |
| 2021 | 292.67 Million INR | 14.56% |
| 2020 | 255.47 Million INR | 5.28% |
| 2019 | 242.67 Million INR | -15.61% |
| 2018 | 287.56 Million INR | -17.07% |
| 2017 | 346.76 Million INR | 94.78% |
| 2016 | 178.02 Million INR | 11.71% |
| 2015 | 159.36 Million INR | 139.85% |
| 2014 | 66.44 Million INR | -16.63% |
| 2013 | 79.7 Million INR | 376.96% |
| 2012 | 16.71 Million INR | -72.57% |
| 2011 | 60.9 Million INR | -48.34% |
| 2010 | 117.89 Million INR | -78.34% |
| 2009 | 544.18 Million INR | 15.37% |
| 2008 | 471.68 Million INR | 4.47% |
| 2007 | 451.49 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q4 | 363.82 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 280.99 Million INR | 0.0% |
| 2023 FY | 363.82 Million INR | 14.6% |
| 2022 Q4 | 317.48 Million INR | 0.0% |
| 2022 FY | 317.48 Million INR | 8.48% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 340.94 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 200.55 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 292.67 Million INR | 14.56% |
| 2021 Q4 | 292.67 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q2 | 259.46 Million INR | 0.0% |
| 2020 FY | 255.47 Million INR | 5.28% |
| 2020 Q4 | 255.47 Million INR | 0.0% |
| 2019 FY | 242.67 Million INR | -15.61% |
| 2019 Q2 | 282.5 Million INR | 0.0% |
| 2019 Q4 | 242.67 Million INR | 0.0% |
| 2018 Q4 | 287.56 Million INR | 0.0% |
| 2018 FY | 287.56 Million INR | -17.07% |
| 2017 Q4 | 346.76 Million INR | 0.0% |
| 2017 FY | 346.76 Million INR | 94.78% |
| 2016 Q2 | 375.61 Million INR | 0.0% |
| 2016 Q4 | 178.02 Million INR | 0.0% |
| 2016 FY | 178.02 Million INR | 11.71% |
| 2015 Q2 | 275 Million INR | 0.0% |
| 2015 Q4 | 159.36 Million INR | 0.0% |
| 2015 FY | 159.36 Million INR | 139.85% |
| 2014 FY | 66.44 Million INR | -16.63% |
| 2014 Q2 | 71.63 Million INR | 0.0% |
| 2014 Q4 | 66.44 Million INR | 0.0% |
| 2013 Q2 | 43.47 Million INR | 0.0% |
| 2013 FY | 79.7 Million INR | 376.96% |
| 2013 Q4 | 79.7 Million INR | 0.0% |
| 2012 Q2 | 44.57 Million INR | 0.0% |
| 2012 Q4 | 16.71 Million INR | 0.0% |
| 2012 FY | 16.71 Million INR | -72.57% |
| 2011 Q4 | 60.9 Million INR | 0.0% |
| 2011 FY | 60.9 Million INR | -48.34% |
| 2010 FY | 117.89 Million INR | -78.34% |
| 2009 FY | 544.18 Million INR | 15.37% |
| 2008 FY | 471.68 Million INR | 4.47% |
| 2007 FY | 451.49 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 42.14% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 98.296% |
| Glenmark Life Sciences Limited | 147.61 Million INR | -146.477% |
| Granules India Limited | 689.71 Million INR | 47.25% |
| Indoco Remedies Limited | 3.51 Billion INR | 89.656% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 235.2 Million INR | -54.687% |
| Alkem Laboratories Limited | 400 Million INR | 9.044% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -10105.442% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -1207.027% |
| Bajaj HealthCare Limited | 650.34 Million INR | 44.057% |
| Bliss GVS Pharma Limited | 355.92 Million INR | -2.22% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 93.926% |
| Eris Lifesciences Limited | 6.54 Billion INR | 94.441% |
| FDC Limited | 2.46 Million INR | -14653.609% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 76.015% |
| Gufic Biosciences Limited | 1.53 Billion INR | 76.369% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -225.931% |
| Ipca Laboratories Limited | 5.8 Billion INR | 93.732% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -381.44% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 80.173% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 95.771% |
| Lupin Limited | 1.55 Billion INR | 76.57% |
| Mankind Pharma Limited | 248.67 Million INR | -46.304% |
| Medicamen Biotech Limited | 12.55 Million INR | -2797.841% |
| Medico Remedies Limited | 8.67 Million INR | -4095.387% |
| Megasoft Limited | 1.35 Billion INR | 73.19% |
| NATCO Pharma Limited | 53 Million INR | -586.46% |
| Piramal Pharma Limited | 24.83 Billion INR | 98.535% |
| RPG Life Sciences Limited | -30.3 Million INR | 1300.739% |
| Sigachi Industries Limited | 265.79 Million INR | -36.88% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -2635.519% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | -71.327% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 29946.103% |
| Unichem Laboratories Limited | 382.22 Million INR | 4.813% |
| Wanbury Limited | 820 Million INR | 55.631% |
| Windlas Biotech Limited | 20.18 Million INR | -1702.894% |
| ZIM Laboratories Limited | 356 Million INR | -2.196% |
| Zydus Lifesciences Limited | 251 Million INR | -44.95% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -241.298% |
| Divi's Laboratories Limited | 20 Million INR | -1719.12% |
| Hester Biosciences Limited | 1.81 Billion INR | 79.985% |
| Procter & Gamble Health Limited | 68.8 Million INR | -428.814% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -2504.696% |
| Strides Pharma Science Limited | 6.71 Billion INR | 94.582% |
| Venus Remedies Limited | 386.8 Million INR | 5.94% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -90856.0% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 74.07% |
| Shilpa Medicare Limited | 5.6 Billion INR | 93.505% |
| Aarti Drugs Limited | 2.75 Billion INR | 86.786% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 96.396% |
| Valiant Laboratories Limited | 746.63 Million INR | 51.271% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | -53.902% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 65.622% |
| Themis Medicare Limited | 267.74 Million INR | -35.887% |
| Hikal Limited | 4.22 Billion INR | 91.396% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 97.732% |
| Sequent Scientific Limited | 1.42 Billion INR | 74.508% |
| Novartis India Limited | 50.7 Million INR | -617.602% |
| Wockhardt Limited | 8.91 Billion INR | 95.917% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 98.851% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 449.2 Million INR | 19.007% |
| Morepen Laboratories Limited | 33.64 Million INR | -981.522% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | -172.444% |